AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $229.12, giving the company a market capitalization of 404.94B. It carries a P/E multiple of 169.90 and pays a dividend yield of 2.9%.
As of 2025-11-12, AbbVie(ABBV) stock has fluctuated between $221.97 and $229.15. The current price stands at $229.12, placing the stock +3.2% above today's low and -0.0% off the high.
The AbbVie(ABBV)'s current trading volume is 729.69K, compared to an average daily volume of 6.19M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $163.81.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $163.81.
ABBV News
How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment 10/03/2025 As the former BeiGene gears up to battle AbbVie and J&J, shares of...
AbbVie delivered third-quarter results that beat analyst expectations for both revenue and earnings per share, driven by continued strength in its immunology an...
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model ba...
Analyst ratings
63%
of 32 ratingsMore ABBV News
Key Points Skyrizi and Rinvoq sales are pushing AbbVie's sales higher. UnitedHealth Group raised its full-year guidance and is rebounding from a disastrous 20...
These stocks are priced low, have encouraging growth prospects, and also pay dividends. A $5,000 investment may not seem like a large amount of money to invest...
AbbVie Inc. recently reported third-quarter results with sales of US$15.78 billion and net income of US$186 million, announced a quarterly dividend increase to...
UBS analyst Trung Huynh raised the firm’s price target on AbbVie (ABBV) to $220 from $195 and keeps a Neutral rating on the shares. The firm updated its model f...